Peptide therapeutics for healing, metabolic health, recovery and wellness have entered a new chapter in Arkansas.
Following the Food and Drug Administration’s Pharmacy Compounding Advisory Committee meetings July 23-24, the panel recommended six peptides for inclusion on the Section 503A Bulk Drug Substances List, clearing a key advisory hurdle toward regulated compounding.
The committee voted in favor of BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax. EmideltidHe, also known as DSIP, was not recommended. The recommendations are advisory and nonbinding; the FDA must still complete formal notice-and-comment rulemaking before the peptides can be legally compounded by 503A pharmacies. The process typically takes months.
Demand in Arkansas has been strong. Dr. Missy Clifton, a triple board-certified dermatologist specializing in laser surgery and antiaging and regenerative medicine at Premier Dermatology, said patients at her northwest Arkansas clinics frequently request BPC-157, TB-500, GHK-Cu, retatrutide, ipamorelin and tesamorelin for weight management and muscle support. Requests also include Thymosin Alpha-1 and LL-37 for immune support, Selank for anxiety, and SEMAX for mental clarity.
Dr. Missy Clifton
Dr. Jeanne Wei, chair of the Donald W. Reynolds Department of Geriatrics at the University of Arkansas for Medical Sciences and executive director of the Reynolds Institute on Aging, said interest tends to be stronger among younger patients while remaining more measured in geriatric populations focused on longevity.
Trent Hollensworth, pharmacist at Little Rock’s Westside Pharmacy, reported consistent inquiries and that BPC-157 was, by far, the most requested.
“Daily phone calls inquire if we’re making them or can make them,” he said.
The FDA’s 2023 Category 2 restrictions had limited traditional compounding of many peptides and contributed to gray-market activity. The late July advisory votes represent a significant step toward regulated pathways for the six recommended substances.
Clifton said she supports expanded compounding with clear safeguards.
“I believe that the FDA should allow the compounding pharmacies to make peptides as long as there is appropriate standardization in dosing and third-party testing on each vial,” she said. “I believe peptides should stay in the supplement category rather than FDA-regulated drugs.”
Hollensworth, who operates under 503A patient-specific rules, had expressed optimism heading into the meetings.
“I’m very skeptical of the quality,” he said of the gray market, adding that regulated compounding can provide a higher-quality option with transparency — patients can observe processes and review testing results and certificates of analysis.
Wei said she supports broader access when guided by healthcare professionals and encouraged patients to consult physicians and pharmacists.
Dr. Jeanne Wei
The experts stressed that recommendations must be paired with caution and evidence. Wei noted that anecdotal reports, while compelling, are not a substitute for rigorous data.
“One anecdotal account is used 500 times over in the absence of real data,” she said, advising caution among older adults.
Hollensworth highlighted the difference between licensed compounding and unregulated sources. Legitimate pharmacies offer measurable quality controls that online research-only products often lack, he said. Clifton said she integrates peptides judiciously in aesthetic and regenerative treatments, emphasizing verified sourcing and third-party testing.
Trent Hollensworth
Arkansas Board of Pharmacy oversight continues to protect consumers through thorough inspections of in-state and out-of-state operations.
The recommendations carry direct implications for the state. Growth in wellness and aesthetics continues in northwest Arkansas, while compounding pharmacies such as Westside are positioned to expand once formal rulemaking is complete. Reaching rural communities remains essential, Wei said, calling for education efforts “grid square by square.”
Challenges remain, including sourcing high-quality materials, formulation development, dosing standardization and affordability.
“I have to find that balance,” Hollensworth said. “If patients can’t afford it, then this is all for naught.”
With six peptides now recommended for the 503A list, the focus shifts to the FDA’s formal rulemaking process, standardization, third-party testing and collaboration among patients, providers and pharmacists.
“Not everything that glitters is gold,” Wei said.
Peptides offer meaningful potential to support healing and wellness for many Arkansans. By drawing on local expertise — from UAMS to specialized clinics and ethical compounding pharmacies — the state can pursue these options responsibly as regulatory clarity develops.
